Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Cash from Operations (2020 - 2026)

Cardiol Therapeutics filings provide 2 years of Cash from Operations readings, the most recent being 9242330.31 for Q4 2022.

  • On a quarterly basis, Cash from Operations fell 191.52% to 9242330.31 in Q4 2022 year-over-year; TTM through Dec 2022 was 20776064.72, a 10.62% decrease, with the full-year FY2025 number at 17073284.19, up 6.73% from a year prior.
  • Cash from Operations hit 9242330.31 in Q4 2022 for Cardiol Therapeutics, down from 1298440.3 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1298440.3 in Q3 2022 to a low of 9242330.31 in Q4 2022.